Plus, ASGE Special Interest Group meeting to also highlight Endoluminal Therapy for GERD
EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced today that the company will host an educational session on the Transoral Incisionless Fundoplication (TIF®) procedure at Digestive Disease Week® (DDW) 2017, which takes place May 6-9, 2017, at McCormick Place in Chicago, Illinois.
The DDW Exhibit Floor Product Theater educational session is on Sunday, May 7, from 1:15 p.m. to 2 p.m. CDT in the DDW Theater in South Hall A. It will include an overview on the TIF procedure and EsophyX® device by Dr. Sameer Islam from University Medical Center, Lubbock, Texas; a review of the TIF procedure clinical data by Dr. Gregory Haber from NYU Langone Medical Center, New York, New York; and a TIF procedure case presentation by Dr. Kenneth J. Chang from UC Irvine Health, Irvine, California.
The American Society for Gastrointestinal Endoscopy (ASGE) Special Interest Group meeting, “Endoluminal Therapy for Esophageal Disease (ETED) & Gastroesophageal Reflux Disease (GERD),” is on Saturday, May 6, from 10-11:30 a.m. CDT at the Hyatt Regency McCormick (HRM) Regency Ballroom D. The topics and speakers are as follows:
- “Role of FLIP on Index EGD: 2017 and Beyond” – Dr. John Pandolfino, an American Gastroenterological Association Fellow (AGAF) from Feinberg School of Medicine, Chicago, Illinois
- “Endoscopic Therapies for GERD: How to Choose?” – Dr. Kenneth Chang, Professor and Chief, Gastroenterology & Hepatology, UC Irvine School of Medicine, Irvine, California
- “Surveillance for Barrett’s Esophagus: Good, Bad and Ugly” – Dr. Steven DeMeester from The Oregon Clinic, Portland, Oregon
In addition, EGS will demonstrate the full line of EsophyX devices at booth #4208 in the DDW exhibit hall. To learn more about the TIF procedure with EsophyX device, visit www.EndoGastricSolutions.com, and visit the DDW Mobile App for more information on these and other sessions.
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 6-9, 2017, at McCormick Place, Chicago, IL. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
Gastroesophageal reflux disease (GERD) is a chronic condition in which the gastroesophageal valve (GEV) allows gastric contents to reflux (wash backwards) into the esophagus, causing heartburn and possible injury to the esophageal lining. GERD is the most common gastrointestinal-related diagnosis made by physicians during clinical visits in the U.S. It is estimated that pain and discomfort from acid reflux impacts over 80 million Americans at least once per month. The standard recommendations for symptomatic GERD patients include lifestyle changes (e.g., diet, scheduled eating times and sleeping positions) and escalating doses of prescription medications for prolonged periods of time. Long-term, maximum-dose usage of prescription medications has been linked to a variety of other health complications.
About Transoral Incisionless Fundoplication (TIF®) procedure for reflux
Performed without the need for external incisions through the skin, the TIF procedure offers patients who require an anatomical repair an effective treatment option to correct the underlying cause of GERD. Studies show that for up to three years after the TIF procedure, esophageal inflammation (esophagitis) is eliminated and most patients are able to stop using daily medications to control symptoms.
More than 18,000 TIF patients have been treated worldwide since the EsophyX® device was launched. In the past ten years, more than 70 peer-reviewed papers from over 50 centers have been published documenting consistent outcomes on over 1,200 unique study patients. For more information, visit www.GERDHelp.com.
About EsophyX® technology
The EsophyX technology is used to reconstruct the gastroesophageal valve (GEV) and restore its function as a barrier, preventing stomach acids refluxing back into the esophagus. The device is inserted through the patient’s mouth with direct visual guidance from an endoscope. The original EsophyX device was cleared by the U.S. Food and Drug Administration in 2007. EndoGastric Solutions® launched the third generation EsophyX device, the EsophyX Z model, in 2015. The evolving EsophyX technology now enables surgeons and gastroenterologists to use a wider selection of endoscopes – including low profile and larger high-definition models — to treat the underlying anatomical cause of GERD.
The EsophyX device with SerosaFuse® fasteners is indicated for use in transoral tissue approximation, full thickness plication and ligation in the gastrointestinal tract and is indicated for the treatment of symptomatic chronic GERD in patients who require and respond to pharmacological therapy. It is also indicated to narrow the gastroesophageal junction and reduce hiatal hernia ≤ 2cm in size in patients with symptomatic chronic GERD.
About EndoGastric Solutions®
Based in Redmond, WA, EndoGastric Solutions, Inc. (https://www.endogastricsolutions.com), is a medical device company focused on developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. Join the conversation on Twitter: @GERDHelp, Facebook: GERDHelpcom and Google+: GERDHelp.
# # #
EndoGastric Solutions®, Inc.